An informational report based on materials provided by MetaFit Pharma Solutions LLC detailing how the TrimRx telehealth platform presents its GLP-1 medication options, compounded and FDA-approved ...
With me on today's call are Relmada Therapeutics, Inc.'s CEO, Dr. Sergio Traversa, who will briefly provide a summary of recent business highlights; Dr. Raj S. Pruthi, Relmada Therapeutics, Inc.'s CMO ...
How a cocaine-positive truck driver exploited a federal self-certification loophole to clear 1,000 prohibted Clearinghouse violations The post 1 in 85: The cocaine-positive truck driver turned ...
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 Earnings Call Transcript March 19, 2026 Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results